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879-1 initial U.S. Experience With Membrane-Covered Stents 
in the Treatment of Saphenous Vein Graft Lesions: Roii- 
in Phase of the BARRICADE Trial 
Bassam Roukoz. Heidar Arjomand, Satish Surabhi, Andrey Espinoza. Gregg W. Stone, 
Donald S. Bairn, Daniel McCormick. Sheldon Goldberg, Hahnemann University Hospital, 
Philadelphia, PA 
Background: Percutaneous interventions in degenerated saphenous vein bypass grafts 
are associated with a high risk of periprocedural distal embolization resulting in myocar- 
dial infarction. We report the in-hospital outcomes of placement of a new polytetrafluore- 
oethylene-covered stent in the first US experience with this device. Methods: As palt of 
a prospective randomized multicenter trial (BARRICADE Trial), 88 patients were 
included in the roll-in phase with 104 lesions in SVGs. The use of distal protection 
devices was left to the discretion of the operator. In-hospital technical success, complica- 
tions rats, and the incidence of MACE (death, Q-wave or non-Q-wave myocardial infarc- 
tion (Ml), and target vessel revascularization (TVR) were analyzed. Results: A total of 88 
patients with a mean age of 67 years received 111 covered stents for 104 stenoses in 
vein grafts 10.2 * 5.8 years after bypass surgery. Clinical characteristics included: diabe- 
tes (35%), hyperlipidemia (92%), hypertension (77%), and smoking (67%). Lesions char- 
acteristics included: reference diameter 3.7 * 0.4 mm, lesion length 15.1 f 5.9 mm, 
percent stenosis 84.2 r 10.2%. Stent placement was successful in all patients. GP Ilb/llla 
inhibitors were used in 66% and distal protection devices in 31% of cases. Complications 
and MACE rates are shown in the table below. Conclusion: The use of PTFE-covered 
stems appears to be safe and effective in treating high risk lesions in SVGs, with a rela- 
tively low risk of non-Q wave myocardial infarction. 
In-hospital Complications and MACE 
Number % 
0 0 
Non-cardiac(bleeding) 
1 1.1 
Q-wave Ml 1 1.1 
Non-Q-wave Ml 8 6.8 
TVR (abrupt closure) 1 1.1 
Any event 8 9 
Major vascular events 2 2.2 
10:45 a.m. 
879-2 Comparison of Saphenous Vein Graft intervention With 
Bare Stents Pius Distal Protection Versus Membrane- 
Covered Stents Without Distal Protection: Data From 
SAFER and Roil-In Phase of BARRICADE Trials 
Heidar Arjomand, Bassam Roukoz, Satish Surabhi, Andrey Espinoza, Marc Cohen, 
Gregg W. Stone, Donald S. Bairn, Zoltan G. Turi, Sheldon Goldberg, Drexel University 
College of Medicine, Philadelphia, PA, Lenox Hill Hospital, New York, NY 
Background: Intervention in saphenous vein graft (SVG) lesions is associated with a 
high risk of cardiac events particularly non-Q wave Ml. Distal protection reduces adverse 
cardiac events. However, there is limited data on the effectiveness of membrane-covered 
stsnts in treating SVG lesions. 
Methods: We compared SVG intervention with bare stents plus distal protection in the 
Guard wire group of SAFER (Saphenous Vein Free of Emboli Randomized) trial with 
membrane-covered stents without distal protection in the roll-in phase of BARRICADE 
(Barrier Approach to Restenosis: Restrict lntima and Curtail Adverse Evens) trial. In 
SAFER, 406 patients were randomized to bars stents plus distal protection. The roll-in 
phase of BARRICADE trial included 59 patients without distal protection, who comprise 
the comparison group. 
Results: Characteristics of patients in SAFER and BARRICADE were: age (68 +/- 10 vs 
67 +/- 8), male (82% vs 75%), diabetes mellitus (33% YS 81%), and rest angina (39% vs 
27%). All patients received aspirin and clopidogrel. Ilb/llla inhibitors were given in 57% 
and 68% of patients respectively. Major adverse cardiac events at 30 days are shown 
(table). 
Conclusions: These preliminary data suggest that a simple strategy of covered-stent 
placement for SVG lesions offer similar outcomes as bare stents combined with distal 
protection. A prospective trial comparing these two strategies is warranted. 
Major Adverse cardiac Events at 30 Days. 
Variable, n (%) SAFER Trial BARRICADE Trial p value 
N=406 N=59 
Death 4 (1.0) 1 (1.7) 0.88 
Q-wave Ml 5 (1.2) 1 (1.7) 0.79 
Non-Q wave Ml (CK-MB > 3x ULN) 30 (7.4) 4 (6.8) 0.68 
Repeat PCI 1 (1.7) 
Composite endpoint 39 (9.8) 7 (11.9) 0.62 
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879-3 Pilot Study With Oral Rapamycin in Patients 
Undergoing Stenting in Coronary Arteries: Buenos 
Aires Experience (ORAR Trial) 
Alfred0 E. Rodriauez, Maxim0 J. Rodriguez Alemparte, Carlos Fernandez Pereira, Cesar 
F. Vigo, Claudia Llaurado, Miguel Russo Felsen, Oberdan Andrin, Jorge L. Martinez, 
Otamendi Hospital, Buenos Aires, Argentina 
Background: Rapamycin Stent coated is associated with low restenosis. The use of oral 
rapamycin to prevent restenosis is unknown. Yethods:From December 2001 to Febru- 
ary 2002, 34 patients (pts) with 49 lesions were treated during one month with oral rapa- 
mycin. In different epicardial coronary vessels 49 stents were deployed. Rapamycin was 
given in a daily dose of 2 mg. stalting with a loaded dosis of 6 mg. Rapamycin blood lev- 
els were measured in all pts during the third week of treatment. Cholesterol and triglycer- 
ides were evaluated before and one month after treatment. Independently of lipid values 
statins were given in all pts as well clopidrogrel during six months. Angiographic binary 
restenosis (a 50%). target vessel revascularization (TVR), target lesion revasculariza- 
tion, treatment compliance and major adverse events were analyssd. Six months follow 
up angiogram was available in 98% of lesions (48/49). Results: Baseline characteristics 
showed diabetics in 32%. in Stent rsstanosis in 32%, type 82 and C lesions in 49%, ves- 
sel size < 2.9 mm in 55% and with a lesion lenght of 11.9 + 0.23 mm. One patient at day 
21 discontinued the medication for Skin rash and fever (3%). There were no other side 
effects in this cohort of pts. Follow up cholesterol and triglycerides showed no changes 
compared to basal levels. Angiographic restenosis was present in 23 % of lesions (1 l/ 
48) with a TVR of 22.4% (11/49). Restenosis in the nova lesions was 16.2% (8/37) com- 
pared to 45.4% (5/l 1) in Stent restenosis lesions, p=O.108. Restenosis in nova lesions 
with rapamycin blood level > 8 ng/ml was not founded (O/10) whereas was 22.2% (6/27) 
when the rapamycin blood level was < 8 nglml, p= 0.309. Conclusions: In this pilot 
obsewational study oral rapamycin taking during one month was safe and well tolerated. 
High rapamycin blood level appears to be associated with lower restenosis rats. 
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879-4 Oral Siroiimus for Recalcitrant InStent Restenosis 
Paul S. Teirstein, Prabhtej S. Brara, Eileen Anderson, Mark A. Grise, Mehran 
Moussavian, John P. Reilly, Mindy R. Fsrnandez, Scripps Clinic, La Jolla, CA 
Background: Sirolimus coated Stents are a promising new therapy for restenosis. At 
Scripps clinic we offered oral sirolimus to a select group of “no-option” patients at espe- 
cially high risk for restenosis. These patients were followed for side effects and need for 
repeat revascularizations. 
Methods: Patients were treated with a sirolimus loading doss of 6 mg after PTCA, fol- 
lowed by 2 mglday for 4 weeks. A one month course of therapy was selected because in 
the RAVEL trial, efficacy was demonstrated using stents that delivered Sirolimus over a 
4-6 week duration. Serum electrolyies, lipid profile, renal panel, and complete blood cell 
count were measured at 1,3. and 5 weeks after drug initiation. 
Results: Oral sirolimus was prescribed to 22 patients with 28 lesions at high risk for rest- 
enosis. Patient age was 57,.1 +/- 10.6 years, 9(41%) were diabetics, and 20(91%) had 
previous brachytherapy failure. The mean number of previous restsnoses per patient 
was 3.5 +/- 1.6. Of the 22 study patients, 11(50%) discontinued oral sirolimus early due 
to side effects or laboratory abnormalities. The mean treatment duration for patients that 
discontinued medication early was 14.5 +/- 6.5 days. Hypertriglceridemia and leukopenia 
were the most frequent adverse events, occurring in 3 patients each. All adverse drug 
effects were reversible after discontinuation. Follow up was obtained in 100% of patients 
at a mean of 10 +I- 2 months, ranging from 6.5-12 months. Target lesion revasculariza- 
tion occurred in 15 of 28 lesions (54%) and 13 of 22 patients (59%). There was no differ- 
ence in TLR for patients receiving a complete 30 day course of Sirolimus 8(62%) 
compared to patients who terminated treatment prematurely 5(38 %), p=NS. Clinically 
driven repeat cardiac catheterization was obtained in 15 (68%) patients; restensosis 
(z&I% diameter stenosis at follow-up) was present in 13(87%). 
Conclusion: Oral sirolimus does not appear to provide benefit to patients with recalcitrant 
restenosis. Adverse drug effetis are frequent. underscoring the importance of local drug 
delivery to achieve high tissue concentrations without systemic adverse drug effects. 
